search for




 

Update on Diagnosis and Treatment of Retinopathy of Prematurity
Ann Optom Contact Lens 2018;17:83-88
Published online December 25, 2018
© 2018 The Korean Optometry & Contact Lens Study Society

Hwan Heo, MD, PhD

Department of Ophthalmology, Chonnam National University Medical School, Gwangju, Korea
Correspondence to: Hwan Heo, MD, PhD
Department of Ophthalmology, Chonnam National University Medical School, #42 Jebong-ro, Dong-gu, Gwangju 61469, Korea
Tel: 82-62-220-6743, Fax: 82-62-227-1642
E-mail: opheye@hanmail.net
Received October 24, 2018; Revised December 8, 2018; Accepted December 8, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Retinopathy of prematurity is still the leading cause of blindness in children. It is on the rise due to the development of postnatal care technology in developing and developed countries. However, due to the lack of experts, appropriate diagnosis and treatment are often not available. Therefore, it is necessary to develop technologies such as telemedicine and diagnostic automation technology for retinopathy of prematurity. Experts should know that the difference of timing and nature of recurrence between intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection and laser treatment. And, after verifying safety dose and systemic complication, guidelines for safe use of intravitreal anti-VEGF injection should be developed.
Keywords : Bevacizumab; Ranibizumab; Retinopathy of prematurity; Telemedicine


December 2018, 17 (4)